BioMarin

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BioMarin and other ETFs, options, and stocks.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,401

Employees3,401

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,401

Employees3,401

BMRN Key Statistics

Market cap

15.68B

Market cap15.68B

Price-Earnings ratio

76.82

Price-Earnings ratio76.82

Dividend yield

—

Dividend yield—

Average volume

2.16M

Average volume2.16M

High today

$83.09

High today$83.09

Low today

$81.59

Low today$81.59

Open price

$81.90

Open price$81.90

Volume

180.98K

Volume180.98K

52 Week high

$99.56

52 Week high$99.56

52 Week low

$76.02

52 Week low$76.02

BMRN News

Yahoo Finance 1h

BioMarin Pharmaceutical Inc. Q1 2024 Earnings Call Transcript - Yahoo Finance

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript April 24, 2024 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported E...

Simply Wall St 2h

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Simply Wall St

Last week, you might have seen that BioMarin Pharmaceutical Inc. ( ) released its first-quarter result to the market. The early response was not positive, with...

Simply Wall St 3h

BioMarin Pharmaceutical First Quarter 2024 Earnings: EPS Beats Expectations

BioMarin Pharmaceutical (NASDAQ:BMRN) First Quarter 2024 Results Key Financial Results Revenue: US$648.8m (up 8.8% from 1Q 2023). Net income: US$88.7m (up 74...

Analyst ratings

70%

of 30 ratings

Buy

70%

Hold

30%

Sell

More BMRN News

Seeking Alpha 18h

BioMarin stock falls 9% in wake of Q1 report, pipeline updates

Shares of BioMarin (BMRN) were down 9% in afternoon trading Thursday, the day after the company released a Q1 revenue report that fell short of expectations and...

Benzinga 22h

Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings) - Biomarin Pharmaceutical - Benzinga

Loading... Loading... In the preceding three months, 8 analysts have released ratings for Biomarin Pharmaceutical BMRN, presenting a wide array of perspectives...

TipRanks 1d

BioMarin price target raised to $85 from $83 at Scotiabank

Scotiabank raised the firm’s price target on BioMarin to $85 from $83 and keeps a Sector Perform rating on the shares following model adjustments. While the com...

Yahoo Finance 1d

BioMarin drops drug programs in pipeline cull - Yahoo Finance

Dive Brief: BioMarin on Wednesday said it’s wrapped up a pipeline review and will stop investing in four experimental therapies because they don’t meet its thr...

Reuters 1d

Q1 2024 Biomarin Pharmaceutical Inc Earnings Call

Participants Alexander Hardy; President, CEO & Director; BioMarin Pharmaceutical Inc. Brian R. Mueller; CFO & Executive VP; BioMarin Pharmaceutical Inc. Henr...

Yahoo Finance 2d

BioMarin Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

For the quarter ended March 2024, BioMarin Pharmaceutical (BMRN) reported revenue of $648.83 million, up 8.8% over the same period last year. EPS came in at $0....

Yahoo Finance 3d

Is a Surprise Coming for BioMarin This Earnings Season? - Yahoo Finance

Investors are always looking for stocks that are poised to beat at earnings season and BioMarin Pharmaceutical Inc. BMRN may be one such company. The firm has e...